These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34154613)

  • 1. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
    Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
    J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
    Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
    Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
    [No Abstract]   [Full Text] [Related]  

  • 3. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
    Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
    Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16
    Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T
    Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
    Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated Fibroblast-derived Extracellular Vesicles Mediate Immune Escape of Bladder Cancer via PD-L1/PD-1 Expression.
    Feng R; Li Z; Ge G; Wang C; Jia Y; Ouyang J
    Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1410-1420. PubMed ID: 36852791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation.
    Chen X; Xie W; Gu P; Cai Q; Wang B; Xie Y; Dong W; He W; Zhong G; Lin T; Huang J
    Sci Rep; 2015 Feb; 5():8293. PubMed ID: 25656485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
    Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
    Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Receptor Transcriptionally Inhibits Programmed Death Ligand-1 Expression and Influences Immune Escape in Bladder Cancer.
    Sun A; Luo Y; Xiao W; Zhu Z; Yan H; Miao C; Zhang W; Bai P; Liu C; Yang D; Shao Z; Song J; Wu Z; Chen B; Xing J; Wang T
    Lab Invest; 2023 Jul; 103(7):100148. PubMed ID: 37059268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
    Zhang D; Reyes RM; Osta E; Kari S; Gupta HB; Padron AS; Kornepati AVR; Kancharla A; Sun X; Deng Y; Wu B; Vadlamudi R; Li R; Svatek RS; Curiel TJ
    Cancer Med; 2021 Mar; 10(6):2137-2152. PubMed ID: 33626233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program.
    Huang M; Dong W; Xie R; Wu J; Su Q; Li W; Yao K; Chen Y; Zhou Q; Zhang Q; Li W; Cheng L; Peng S; Chen S; Huang J; Chen X; Lin T
    Cancer Commun (Lond); 2022 May; 42(5):447-470. PubMed ID: 35434944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CircZNF609 promotes bladder cancer progression and inhibits cisplatin sensitivity via miR-1200/CDC25B pathway.
    Feng D; Lv J; Li K; Cao Q; Han J; Yu H; Cheng Y; Zhuang J; Cai L; Yang H; Yang X; Lu Q
    Cell Biol Toxicol; 2023 Oct; 39(5):1-18. PubMed ID: 35567596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
    Neilsen BK; Chakraborty B; McCall JL; Frodyma DE; Sleightholm RL; Fisher KW; Lewis RE
    BMC Cancer; 2018 Jun; 18(1):673. PubMed ID: 29925347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.
    Han QL; Zhang XL; Ren PX; Mei LH; Lin WH; Wang L; Cao Y; Li K; Bai F
    Acta Pharmacol Sin; 2023 Apr; 44(4):877-887. PubMed ID: 36207403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
    Mao S; Zhang J; Guo Y; Zhang Z; Wu Y; Zhang W; Wang L; Geng J; Yan Y; Yao X
    Drug Des Devel Ther; 2019; 13():291-300. PubMed ID: 30666091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade.
    Lv J; Wu Q; Li K; Bai K; Yu H; Zhuang J; Sun H; Yang H; Yang X; Lu Q
    Int J Biol Sci; 2023; 19(12):3744-3761. PubMed ID: 37564199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.